| Literature DB >> 29426018 |
Claire Beausoleil1, Claude Emond2, Jean-Pierre Cravedi3, Jean-Philippe Antignac4, Martine Applanat5, Brice R Appenzeller6, Remy Beaudouin7, Luc P Belzunces8, Marie-Chantal Canivenc-Lavier9, Nicolas Chevalier10, Cécile Chevrier11, Elisabeth Elefant12, Florence Eustache13, René Habert14, Martine Kolf-Clauw15, Brigitte Le Magueresse-Battistoni16, Sakina Mhaouty-Kodja17, Christophe Minier18, Luc Multigner11, Henri Schroeder19, Patrick Thonneau20, Catherine Viguié21, François Pouzaud1, Jean-Nicolas Ormsby1, Christophe Rousselle1, Lauranne Verines-Jouin1, Elodie Pasquier22, Cécile Michel1.
Abstract
BPA is one of the most investigated substances for its endocrine disruptor (ED) properties and it is at the same time in the center of many ED-related controversies. The analysis on how BPA fits to the regulatory identification as an ED is a challenge in terms of methodology. It is also a great opportunity to test the regulatory framework with a uniquely data-rich substance and learn valuable lessons for future cases. From this extensive database, it was considered important to engage in a detailed analysis so as to provide specific and strong evidences of ED while reflecting accurately the complexity of the response as well the multiplicity of adverse effects. An appropriate delineation of the scope of the analysis was therefore critical. Four effects namely, alterations of estrous cyclicity, mammary gland development, brain development and memory function, and metabolism, were considered to provide solid evidence of ED-mediated effects of BPA.Entities:
Keywords: Bisphenol A; ED; Endocrine disruption; REACh; SVHC; Substance of very high concern
Mesh:
Substances:
Year: 2018 PMID: 29426018 DOI: 10.1016/j.mce.2018.02.001
Source DB: PubMed Journal: Mol Cell Endocrinol ISSN: 0303-7207 Impact factor: 4.102